Northern Trust Corp Trims Stake in Omnicell, Inc. $OMCL

Key Points

• Northern Trust Corp reduced its stake in Omnicell, Inc. by 9.8% in the first quarter, now holding approximately 1.09% of the company's stock valued at $17.81 million.
• Several institutional investors have made recent changes to their positions in Omnicell, including Point72 Hong Kong Ltd and Corton Capital Inc., contributing to institutional ownership of 97.70%.
• Omnicell reported $0.45 earnings per share, surpassing analyst expectations of $0.30, and had a revenue of $290.56 million, reflecting a 5.0% year-over-year increase.

Northern Trust Corp decreased its stake in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 9.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 509,436 shares of the company's stock after selling 55,590 shares during the quarter. Northern Trust Corp owned approximately 1.09% of Omnicell worth $17,810,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Point72 Hong Kong Ltd purchased a new position in shares of Omnicell during the 4th quarter valued at about $101,000. Corton Capital Inc. bought a new stake in Omnicell during the 4th quarter worth approximately $208,000. Caption Management LLC bought a new stake in Omnicell during the 4th quarter worth approximately $223,000. Occudo Quantitative Strategies LP purchased a new position in Omnicell during the fourth quarter valued at approximately $286,000. Finally, New Age Alpha Advisors LLC bought a new position in shares of Omnicell in the first quarter worth approximately $233,000. Institutional investors own 97.70% of the company's stock.

Omnicell Stock Performance

NASDAQ:OMCL opened at $32.10 on Wednesday. The company has a market cap of $1.47 billion, a price-to-earnings ratio of 64.20, a PEG ratio of 7.12 and a beta of 0.82. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74. The stock's 50 day simple moving average is $30.21 and its two-hundred day simple moving average is $31.46. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. During the same period last year, the firm posted $0.51 earnings per share. Omnicell's revenue for the quarter was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Analyst Ratings Changes

OMCL has been the topic of several recent analyst reports. Wells Fargo & Company raised their price objective on shares of Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a research report on Monday, July 21st. Wall Street Zen lowered Omnicell from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 9th. Benchmark lowered their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Piper Sandler dropped their price objective on Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Finally, Bank of America lifted their target price on Omnicell from $30.00 to $34.00 and gave the company a "neutral" rating in a research note on Friday, May 23rd. Four equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.